CYP2U1

Across TCGA pan-cancer cohorts, CYP2U1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CYP2U1 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher CYP2U1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP2U1 expression acts as an unfavorable survival marker.

SCLC and PRAD are the cancer types where CYP2U1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	All	0.164	0.625	.018	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CYP2U1–SCLC (DFS)

Open the SCLC breakdown →